Dr. Javad Karimbayli delivered an engaging talk as part of the ongoing seminar series hosted by TRIPM, focusing on innovative strategies to enhance the efficacy of targeted cancer therapies. The session was attended by students and faculty from various departments, fostering an interdisciplinary exchange of ideas. His presentation centered on the role of hypoxia, a common feature of the tumor microenvironment in influencing therapeutic responses in breast cancer.
Dr. Javad Karimbayli’s research focuses on understanding how cancer cells develop resistance to systemic and targeted therapies through experimental and bioinformatic approaches. He earned his Ph.D. in Biomolecular Medicine from the University of Trieste, Italy, in 2022, where he investigated molecular mechanisms of chemotherapy resistance in ovarian cancer, and previously completed a postdoctoral fellowship at the Italian National Cancer Institute, CRO Aviano. Dr. Karimbayli’s work spans cellular imaging, high-throughput data analysis, and molecular biology techniques, and has resulted in publications in high-impact journals including Molecular Cancer, Science Advances, and Signal Transduction and Targeted Therapy.
In his talk, Dr. Karimbayli explored how hypoxic conditions within tumors can be strategically leveraged to sensitize breast cancer cells to PARP-targeted therapies. By modulating cellular pathways associated with DNA damage response under low-oxygen conditions, hypoxia may enhance the vulnerability of cancer cells to PARP inhibition. These findings highlight a promising therapeutic avenue, particularly for tumors that are otherwise resistant to conventional treatments, and underscore the potential of integrating tumor microenvironment dynamics into the development of more effective cancer therapies.
